Which of the following is NOT required in an Abbreviated New Drug Application (ANDA)?

• A. Preclinical (animal) and clinical (human) data to establish safety and effectiveness
• B. Chemistry, manufacturing, and controls information
• C. Bioequivalence data
• D. Labeling information

Answer: (A)

An ANDA is built for generic drugs, where the goal is to show the product works the same as the brand-name reference without repeating full safety and efficacy trials. Because the safety and effectiveness of the reference product are already established, you don’t need new preclinical or clinical studies to prove safety and efficacy for the generic. Instead, the focus is on proving bioequivalence to the reference, while providing thorough chemistry, manufacturing, and controls information to ensure quality, and labeling that matches regulatory requirements. In routine cases, bioequivalence data, CMC information, and labeling are the core requirements; new animal or human safety/efficacy data isn’t needed unless dealing with special situations like complex generics or new indications.